New approaches for the quantification and targeting of noradrenergic dysfunction in Alzheimer's disease
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51539
Abstract: There is clear, early noradrenergic dysfunction in Alzheimer's disease. This is likely secondary to pathological tau deposition in the locus coeruleus, the pontine nucleus that produces and releases noradrenaline, prior to involvement of cortical brain… read more here.
Keywords: alzheimer disease; dysfunction; dysfunction alzheimer; noradrenergic dysfunction ... See more keywords
Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium
Sign Up to like & getrecommendations! Published in 2021 at "Neuroscience Letters"
DOI: 10.1016/j.neulet.2021.136078
Abstract: Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases, characterized by the accumulation of abnormal tau proteins within neurons and amyloid plaques in the brain parenchyma, which leads to progressive loss of neurons… read more here.
Keywords: dysfunction alzheimer; alzheimer disease; disease; disease therapeutic ... See more keywords
The molecular mechanisms of signal pathway activating effect of E2F-1/NF-κB/GSK-3β on cognitive dysfunction of Alzheimer rats
Sign Up to like & getrecommendations! Published in 2021 at "Bioengineered"
DOI: 10.1080/21655979.2021.1989261
Abstract: ABSTRACT Alzheimer disease (AD) seriously harms human health and its onset is insidious. Therefore, it is of great significance to find out the pathogenesis of AD disease for improving the prevention and treatment effect of… read more here.
Keywords: cognitive dysfunction; alzheimer rats; dysfunction alzheimer; e2f gsk ... See more keywords
Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Aging Neuroscience"
DOI: 10.3389/fnagi.2018.00127
Abstract: Noradrenergic dysfunction contributes to cognitive impairment in Alzheimer's Disease (AD) and Parkinson's Disease (PD). Conventional therapeutic strategies seek to enhance cholinergic and dopaminergic neurotransmission in AD and PD, respectively, and few studies have examined noradrenergic… read more here.
Keywords: dysfunction alzheimer; dysfunction; imaging studies; noradrenergic dysfunction ... See more keywords
Retinal Dysfunction in Alzheimer’s Disease and Implications for Biomarkers
Sign Up to like & getrecommendations! Published in 2021 at "Biomolecules"
DOI: 10.3390/biom11081215
Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that manifests as cognitive deficits and memory decline, especially in old age. Several biomarkers have been developed to monitor AD progression. Given that the retina and brain… read more here.
Keywords: dysfunction alzheimer; alzheimer disease; retinal dysfunction; disease implications ... See more keywords
The Role of Mitochondrial Dysfunction in Alzheimer’s: Molecular Defects and Mitophagy-Enhancing Approaches
Sign Up to like & getrecommendations! Published in 2023 at "Life"
DOI: 10.3390/life13040970
Abstract: Alzheimer’s disease (AD), a progressive and chronic neurodegenerative syndrome, is categorized by cognitive and memory damage caused by the aggregations of abnormal proteins, specifically including Tau proteins and β-amyloid in brain tissue. Moreover, mitochondrial dysfunctions… read more here.
Keywords: role mitochondrial; dysfunction alzheimer; mitochondrial dysfunction; dysfunction ... See more keywords